JAZZ Q4 2018 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$476M+9.2% YoY

Gross Profit

$450M94.5% margin

Operating Income

$185M38.8% margin

Net Income

$159M33.5% margin

EPS (Diluted)

$2.64

QoQ Revenue Growth

+1.5%

Cash Flow

Operating Cash Flow

$224M

Free Cash Flow

$219M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$5.2B

Total Liabilities

$2.4B

Stockholders' Equity

$2.8B

Cash & Equivalents

$310M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$476M	$436M	+9.2%
Gross Profit	$450M	$411M	+9.5%
Operating Income	$185M	$141M	+31.1%
Net Income	$159M	$232M	-31.3%

Revenue Segments

Product And Services, Product Sales

$467M50%

Xyrem

$375M40%

Defitelio/Defibrotide

$38M4%

Vyxeos

$26M3%

Erwinaze And Erwinase

$24M3%

Product And Services, Royalties And Contract Revenue

$9M1%

Other Products

$5M1%

Geographic Segments

UNITED STATES

$437M92%

Europe

$32M7%

Other Countries

$8M2%